Меню
Идёт набор NCT04792684

Collection of Samples USOPTIVAL Study

Наблюдательное Colorectal Cancer (CRC) Advanced Adenomas (AA)

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel.
Кому может быть актуально
Состояния в реестре: Colorectal Cancer (CRC), Advanced Adenomas (AA). Базовые параметры: 45 лет — 84 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance ("USOPTIVAL")

Обзор

A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.

Подробное описание

This study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination.

Subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. By accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit.

Вмешательства

  • Диагностический тест Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
    Evaluate the performance of a preliminary panel of biomarkers

Первичные конечные точки

  • Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing [Срок оценки: Within 12 months of sample collection]

Критерии участия

Критерии включения

Arm A:

  • Must be 45-84 years of age.
  • Must have a suspected advanced adenoma or be newly diagnosed with CRC, still not resected, and scheduled for surgery.
  • Able to comprehend, sign, and date the written informed consent document.

Arm B:

  • Must be 45-84 years of age.
  • Able and willing to undergo a standard-of-care screening colonoscopy within 60 days.
  • Able to comprehend, sign, and date the written informed consent document.

Критерии исключения

Arm A Only:

1\. Subject with curative biopsy during colonoscopy.

Arm B Only:

  • Subjects with positive FIT Test results in the 6 months preceding enrollment.
  • Subject has a current diagnosis of cancer.

Arms A \& B:

  • Subject has a personal history of aerodigestive or digestive tract cancers.
  • Subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer.
  • Has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer:
  • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
  • Familial adenomatous polyposis ("FAP", including attenuated FAP).
  • Hereditary non-polyposis colorectal cancer syndrome ("HNPCC" or "Lynch Syndrome").
  • Serrated polyposis syndrome
  • 2 first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer.
  • One first-degree relative with CRC diagnosed before the age of 60.
  • A significant disease which, in the Investigator's opinion, would exclude the subject from the study.
  • Legal incapacity or limited mental capacity.
  • Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent.
  • The patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (E.g. Hepatitis, HIV, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions.
  • The patient is known to be pregnant when recruited or during her participation in the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Случай-контроль

Центры проведения

США · 16 центров
  • Precision Recearch Institute — Chula Vista
  • Precision Research Institute — San Diego
  • Medical Associates Research Group — San Diego
  • Clinical Research of California — Walnut Creek
  • Center for Gastrointestinal Disorders — Hollywood
  • Lakeland Regional Cancer Center — Lakeland
  • Springfield Clinic — Springfield
  • Ochsner Clinic — New Orleans
  • … и ещё 8 центров

Идентификаторы

NCT: NCT04792684 · CRC-US-001

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗